Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia - From Clinical Data to Individualized Care

Des Moines, IA US
September 1, 2016
Registration


There is no cost to attend.

Two attendance options:

  • Des Moines University - No registration necessary.
  • Online - click here. 

Target Audience

DMU faculty, staff, students, residents, and the medical community.

Purpose

This case-based live activity will cover the diagnosis, treatment, and management of patients with chronic lymphocytic leukemia (CLL). 

Objectives

  • Review disease-risk stratification and the use of a prognostic nomogram for estimating time to treatment.
  • Examine the first-line management of patients with chronic lymphocytic leukemia (CLL) to maximize adherence while minimizing associated adverse events. 
  • Discuss the current treatment options for patients with relapsed/refractory CLL and associated limitations.
  • Explain the late-stage, clinical trial data for emerging therapies in relapsed/refractory CLL.

References

  • Ding W et al. Blood. 2015;126(23): abstract 834.  
  • Porter DL et al. N Engl J Med. 2011;365:725-733.
  • Byrd JC et al. Blood. 2014;123:1302-1308.
  • Sharman J et al. Blood. 2015;125:2336-2343.
  • Awan FT, Byrd JC. Clin Cancer Res. 2014;20:5869-5874.
  • Roberts AW et al. N Engl J Med. 2016;374:311-322.

Educational Grants

This CME activity is sponsored by the Med Learning Group.

Continuing Education Credit

  • MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
  • Nurses: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.2 continuing education contact hour(s). No partial credit awarded.
  • Other healthcare providers: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits™
  • 1.00 AOA Category 2­A
  • 1.00 CE Contact Hour(s)
  • 1.20 IBON
Course opens: 
09/01/2016
Course expires: 
09/01/2016
Event starts: 
09/01/2016 - 7:00am CDT
Event ends: 
09/01/2016 - 8:00am CDT
Cost:
$0.00
Add to calendar: 
Des Moines University
3200 Grand Avenue
SEC Auditorium
Des Moines, IA 50312
United States

Ryan W. Jacobs, MD
Department of Hematology, Levine Cancer Institute, Carolinas Health Care System, Charlotte, NC
Clinical Assistant Professor of Medicine, UNC-Chapel Hill School of Medicine, Chapel Hill, NC

Specialties

  • Hematology - Medical Oncology
  • Internal Medicine

Education

  • Medical School - Baylor College of Medicine
  • Residency - Vanderbilt University Medical Center
  • Fellowship - MD Anderson Cancer Center
  • Internship - Vanderbilt University Medical Center

Board Certification  

  • American Board of Internal Medicine - Hematology
  • American Board of Internal Medicine - Medical Oncology

During the course of this lecture, Dr. Jacobs may mention the use of medications for both FDA-approved and non-approved indications. Dr. Jacobs has no relevant financial relationships to disclose.

Available Credit

  • 1.00 AMA PRA Category 1 Credits™
  • 1.00 AOA Category 2­A
  • 1.00 CE Contact Hour(s)
  • 1.20 IBON

Price

Cost:
$0.00
Please login or Create an Account to take this course.